Repository logo

Browsing by Issue Date, starting with "2014-11"

Filter results by year or month
Now showing 1 - 3 of 3
  • XXVI Reunião de Pediatria do CMIN-CHP: Resumo das comunicações
    Publication . Alvares, S.
    Suplemento da revista Nascer & Crescer com os resumos dos Posters e Comunicações orais apresentadas durante a XXVI Reunião Anual de Pediatria CMIN – CHP que decorreu entre os dias 28 e 29 de novembro de 2014, na cidade do Porto, Portugal
    2014-11Conference object Open access Show more
  • The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study
    Publication . Sousa, L.; de Sa, J.; Sa, M.; Cerqueira, J.; Martins-Silva, A.
    INTRODUCTION: Studies have shown that natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). To date, no data are available in Portuguese patients. AIM: To determine the efficacy and safety of natalizumab in patients with RRMS in routine clinical practice in Portugal. PATIENTS AND METHODS: Clinical data for adult patients with RRMS treated with natalizumab at specialist neurology centres in Portugal were entered retrospectively into a database for analysis between October 2010 and February 2012. Changes in annualized relapse rates (ARR), Expanded Disability Status Scale (EDSS) scores and disability status were analysed. RESULTS: A total of 383 patients from 20 centres were included. Prior to starting natalizumab, the baseline median EDSS score was 4 and the mean ARR was 1.64. Most patients had previously received multiple sclerosis treatment (93.0%). Median natalizumab treatment duration was 12 months. Natalizumab treatment was associated with significant (p < 0.001) reductions from baseline in the mean ARR and EDSS scores in patients treated with natalizumab for >= 12 months (n = 288) and for >= 24 months (n = 160). Natalizumab was more effective in patients with less disability (EDSS < 3) and in those who had not previously received disease-modifying treatments. Two cases of progressive multifocal leukoencephalopathy were reported. No new unexpected adverse events occurred. CONCLUSION: Natalizumab is well tolerated, and is effective in reducing relapse rate and stabilising disease in patients with RRMS in the clinical practice setting in Portugal. Its efficacy persists with continued treatment, and it may be particularly effective in patients with less disability and without prior disease modifying therapy.
    2014-11-01Journal article Open access Show more
  • Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
    Publication . Cabral, R.; Caballero, J.; Alonso, S.; Dávila, J.; Cabrero, M.; Caballero, D.; Vázquez, L.; Sánchez-Guijo, F.; López, L.; Cañizo, M.; Mateos, M.; González, M.
    Detailed knowledge about differentiation syndrome (DS) has remained limited. There are 2 large studies conducted by the Spanish workgroup PETHEMA (Programa Español de Tratamientos en Hematología; Spanish Program on Hematology Treatments) and the European group trial (LPA 96-99 and APL 93) in which the incidence, characteristics, prognostic factors and outcome of patients developing DS are evaluated. Both have described the median time of DS development between 10 and 12 days. The severity of the DS has been evaluated in the study conducted by PETHEMA, and severe DS usually occurs at the beginning of the treatment (median of 6 days), as compared with moderate DS (median of 15 days). We report here in two cases of late severe DS, with late diagnosis due to both time and form of presentation. We discuss the physiopathology, clinical presentation, prophylaxis and treatment of DS.
    2014-11-19Journal article Open access Show more